Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.
You may also be interested in...
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.